AR132159A1 - Anticuerpos anti-b7h3 y métodos de uso - Google Patents

Anticuerpos anti-b7h3 y métodos de uso

Info

Publication number
AR132159A1
AR132159A1 ARP240100660A ARP240100660A AR132159A1 AR 132159 A1 AR132159 A1 AR 132159A1 AR P240100660 A ARP240100660 A AR P240100660A AR P240100660 A ARP240100660 A AR P240100660A AR 132159 A1 AR132159 A1 AR 132159A1
Authority
AR
Argentina
Prior art keywords
antigen
antibody
seq
binding fragment
human
Prior art date
Application number
ARP240100660A
Other languages
English (en)
Inventor
Liang Qu
Yao Ding
Ya Zhang
Original Assignee
Beigene Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh filed Critical Beigene Switzerland Gmbh
Publication of AR132159A1 publication Critical patent/AR132159A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona anticuerpos o fragmentos de unión a antígeno de los mismos que se unen a 4Ig-B7H3 humana. Reivindicación 1: Un anticuerpo o fragmento de unión a antígeno del mismo que se une específicamente a 4Ig-B7H3 humana, comprendiendo el anticuerpo o fragmento de unión a antígeno del mismo: (1) una región variable de la cadena pesada (VH) que comprende (a) una HCDR1 (Región Determinante de la Complementariedad de la Cadena Pesada 1) de SEQ ID Nº 7, (b) una HCDR2 de SEQ ID Nº 8, y (c) una HCDR3 de SEQ ID Nº 9; o (2) una región variable de la cadena pesada que comprende (a) una HCDR1 de SEQ ID Nº 12, (b) una HCDR2 de SEQ ID Nº 13, y (c) una HCDR3 de SEQ ID Nº 14. Reivindicación 7: Un anticuerpo multiespecífico o fragmento de unión a antígeno del mismo que comprende al menos un primer dominio de unión a antígeno que se une específicamente a un primer antígeno tumoral humano (TAA), en donde el primer TAA es 4Ig-B7H3 humana y el primer dominio de unión a antígeno comprende el anticuerpo o fragmento de unión a antígeno del mismo de una cualquiera de las reivindicaciones anteriores; y al menos un segundo dominio de unión a antígeno que se une específicamente a un segundo TAA humano. Reivindicación 15: Una composición farmacéutica que comprende el anticuerpo o fragmento de unión a antígeno del mismo de una cualquiera de las reivindicaciones anteriores y un portador farmacéuticamente aceptable. Reivindicación 16: Un ácido nucleico aislado que codifica el anticuerpo o fragmento de unión a antígeno del mismo de una cualquiera de las reivindicaciones 1 a 14. Reivindicación 17: Un vector que comprende el ácido nucleico de la reivindicación 16. Reivindicación 18: Una célula huésped que comprende el ácido nucleico de la reivindicación 16 o el vector de la reivindicación 17. Reivindicación 19: Un proceso para producir un anticuerpo o fragmento de unión a antígeno del mismo que comprende cultivar la célula huésped de la reivindicación 18 y recuperar el anticuerpo o fragmento de anticuerpo del cultivo.
ARP240100660A 2023-03-17 2024-03-18 Anticuerpos anti-b7h3 y métodos de uso AR132159A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2023082099 2023-03-17

Publications (1)

Publication Number Publication Date
AR132159A1 true AR132159A1 (es) 2025-05-28

Family

ID=92840909

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100660A AR132159A1 (es) 2023-03-17 2024-03-18 Anticuerpos anti-b7h3 y métodos de uso

Country Status (13)

Country Link
US (1) US20260085122A1 (es)
EP (1) EP4680643A1 (es)
JP (1) JP2026509454A (es)
KR (1) KR20250160360A (es)
CN (1) CN120958028A (es)
AR (1) AR132159A1 (es)
AU (1) AU2024237990A1 (es)
CL (1) CL2025002783A1 (es)
CO (1) CO2025013921A2 (es)
IL (1) IL323120A (es)
MX (1) MX2025010929A (es)
TW (1) TW202438527A (es)
WO (1) WO2024193450A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026128367A1 (en) * 2024-12-09 2026-06-18 Y-Mabs Therapeutics, Inc. Tumor binding molecules and the use thereof for the diagnosis and treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110642948B (zh) * 2019-10-09 2021-06-29 达石药业(广东)有限公司 B7-h3纳米抗体、其制备方法及用途
CA3156761A1 (en) * 2019-10-22 2021-04-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CN115942978A (zh) * 2020-06-26 2023-04-07 尹图赛利有限公司 包含抗b7-h3抗体的抗体-药物缀合物
AU2022301099A1 (en) * 2021-07-01 2024-02-15 Ningbo T-Maximum Biopharmaceuticals Co., Ltd. Antigen-binding polypeptide targeting b7h3 and application thereof

Also Published As

Publication number Publication date
MX2025010929A (es) 2025-10-01
WO2024193450A9 (en) 2025-10-09
WO2024193450A1 (en) 2024-09-26
CO2025013921A2 (es) 2025-10-20
CN120958028A (zh) 2025-11-14
AU2024237990A1 (en) 2025-09-25
IL323120A (en) 2025-11-01
EP4680643A1 (en) 2026-01-21
TW202438527A (zh) 2024-10-01
KR20250160360A (ko) 2025-11-12
JP2026509454A (ja) 2026-03-19
CL2025002783A1 (es) 2026-01-02
US20260085122A1 (en) 2026-03-26

Similar Documents

Publication Publication Date Title
AR123083A1 (es) Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos
AR110755A1 (es) Anticuerpos dirigidos a hueso
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
JP2020534830A5 (es)
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
JP2021184710A (ja) 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途
AR123997A1 (es) ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
JP2017521054A5 (es)
AR129935A1 (es) Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos
CO2018001256A2 (es) Anticuerpos anti-cd154 y métodos para producir los mismos
PE20230616A1 (es) Anticuerpos que se unen a cd3 y folr1
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
AR129991A1 (es) Anticuerpos que se unen a la pad4 humana y usos de los mismos
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
AR125074A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
AR110967A1 (es) Anticuerpos miméticos fgf21 y su uso
PE20240589A1 (es) ANTICUERPOS CD1a Y SU USO
AR124917A1 (es) Moléculas de unión a vegfa
AR131528A1 (es) Anticuerpos anti-b7h3 y métodos de uso
AR132064A1 (es) Anticuerpos anti-cldn6 y métodos de uso
AR132041A1 (es) Anticuerpos cd16a y métodos de uso
AR130865A1 (es) Agentes de unión de msln y cd3 y métodos de uso de estos
AR130130A1 (es) Proteínas de unión al receptor de transferrina para tratar tumores cerebrales
AR132043A1 (es) Anticuerpos muc1 y métodos de uso
AR125040A1 (es) Constructos anti-vista y usos de estos